Efficacy of intravesical nadofaragene firadenovec for patients with bcg-unresponsive carcinoma in situ of the bladder: 36-month follow-up from a phase 3 trial

Urologic Oncology: Seminars and Original Investigations(2024)

引用 0|浏览11
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要